SCHEMBL2185108

SCHEMBL2185108

O=C(Nc1ccc(F)c(Cl)c1)c1cc(N2CCOCC2)no1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.61
MEN1 O00255 4/20 0.61
LMNA P02545 6/20 0.55
HTT P42858 4/20 0.55
PIK3CD O00329 2/20 0.55
CYP3A4 P08684 2/20 0.55
AKT1 P31749 2/20 0.55
PIK3CB P42338 2/20 0.55
PIK3CG P48736 2/20 0.55
PIK3CA P42336 1/20 0.55
SMN1; SMN2 Q16637 10/20 0.54
MAPT P10636 4/20 0.54
TSHR P16473 1/20 0.54
NPC1 O15118 5/20 0.53
RAB9A P51151 5/20 0.53
ALDH1A1 P00352 3/20 0.53
HPGD P15428 3/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
MAPK1 P28482 2/20 0.52
TP53 P04637 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12506964 0.87 LMNA (0.52) KMT2AMEN1LMNAHTTPIK3CD
SCHEMBL12415216 0.86 LMNA (0.51) KMT2AMEN1LMNAHTTPIK3CD
SCHEMBL2183729 0.78 KMT2A (0.74) KMT2AMEN1LMNACYP3A4SMN1; SMN2
SCHEMBL2184575 0.74 IDO1 (0.49) PIK3CDPIK3CBPIK3CA
SCHEMBL20236301 0.74 MAPT (0.77) KMT2AMEN1LMNASMN1; SMN2MAPT
SCHEMBL13901998 0.73 SMN1; SMN2 (0.64) KMT2AMEN1LMNAHTTCYP3A4
SCHEMBL1028454 0.71 AKT1 (1.00) PIK3CDCYP3A4AKT1PIK3CBPIK3CG
SCHEMBL18226644 0.71 LMNA (0.54) KMT2AMEN1LMNAHTTPIK3CD
SCHEMBL2184331 0.71 MEN1 (0.54) KMT2AMEN1SMN1; SMN2MAPTHPGD
SCHEMBL13901999 0.71 RAB9A (0.66) KMT2AMEN1LMNAHTTCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2064194-B1 N-HYDROXYAMIDINOHETEROCYCLIC COMPOUNDS AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE HOLDINGS CORP (US) 2018-11-07 EP disclosed
US-8507541-B2 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase INCYTE CORPORATION (US) 2013-08-13 US disclosed
US-8507541-B2 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase INCYTE CORPORATION (US) 2013-08-13 US disclosed
US-8507541-B2 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase INCYTE CORPORATION (US) 2013-08-13 US disclosed
US-20110165188-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE Incyte Corporation a Delaware corporation 2011-07-07 US disclosed
US-20110165188-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE Incyte Corporation a Delaware corporation 2011-07-07 US disclosed
US-20110165188-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE Incyte Corporation a Delaware corporation 2011-07-07 US disclosed
EP-2064194-A2 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE Incyte Corporation (US) 2009-06-03 EP disclosed
US-20080214546-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2008-09-04 US disclosed
US-20080214546-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2008-09-04 US disclosed
US-20080214546-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2008-09-04 US disclosed
WO-2008036653-A2 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2008-03-27 WO disclosed
WO-2008036653-A2 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2008-03-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214546-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE IDO1, IDO2, HNMT KMT2A 675/4885MEN1 2391/4885LMNA 4753/4885
US-20110165188-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE IDO1, IDO2, HNMT KMT2A 675/4885MEN1 2391/4885LMNA 4753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.